Determination of succinylacetone levels in a part of healthy child population in Slovakia

Czech version

Authors: G. Addová; R. Górová; H. Jurdáková
Authors‘ workplace: Chemický ústav, Prírodovedecká fakulta, Univerzita Komenského, Bratislava, Slovensko
Published in: Čes-slov Pediat 2020; 75 (2): 91-96.
Category: Original Papers

Overview

Objective: The aim of the study was to obtain a physiological range of succinylacetone as a marker for tyrosinemia type I in part of the child population in Slovakia.

Methods: To achieve the target, direct injection tandem mass spectrometry was applied, a commercial kit of Chromsystems for amino acids and acylcarnitines and succinylacetone with derivatization was used for the dry blood sample pre-treatment.

Results: The physiological range of the SUAC, in our sample set and by chosen pre-treatment, as measured in the dry blood spot is from 0.32 to 0.70 µmol/L, with average of 0.50 µmol/L and a median of 0.49 µmol/L.

Conclusion: In view of its advantage of simultaneous determination amino acids, acylcarnitines and succinylacetone from a single dry blood sample, for very important early detection of tyrosinemia I, is this method suitable for routine practice in laboratories dealing with hereditary metabolic diseases.

Keywords:

screening – tyrosinemia – succinylacetone – dry blood spot – tandem mass spectrometry

Sources

1. Mitchell GA, Grompe M, Lambert MR, et al. Hypertyrosinemia. In: Scriver CR, et al. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill, 2001: 1777–1805.

2. Holme E, Lindstedt S. Diagnosis and management of tyrosinemia type I. Curr Opin Pediatr 1995; 7 (6):726–732.

3. Dashti AS, Hamzavi SS. Tyrosinemia presenting with multiple hepatic lesions and splenomegaly. J Clin Gastroenterol 2019; 53 (1): 76–77.

4. Giguère Y, Berthier MT. Newborn screening for hereditary tyrosinemia type I in Québec. Adv Exp Med Biol 2017; 959: 139–146.

5. Verma IC. Burden of genetic disorders in India. Ind J Pediatr 2000; 67 (12): 893–898.

6. Nasrallah F, Souissi M, Feki M, et al. Tyrosinemia type I: prevalence and clinical and biochemical profile in Tunisia. J Inherit Metab Dis 2005; 28 (Suppl 1): 58.

7. De Braekeleer M, Larochelle J. Genetic epidemiology of hereditary tyrosinemia in Quebec and Saguenay-Lac-St-Jean. Am J Hum Genet 1990; 47 (2): 302–307.

8. Bliksrud YT, Brodtkorb E, Backe PH, et al. Hereditary tyrosinaemia type I in Norway: incidence and three novel small deletions in the fumarylacetoacetase gene. Scand J Clin Lab Invest 2012; 72 (5): 369–373.

9. Turgeon C, Magera MJ, Allard P, et al. Combined newborn screening for succinylacetone, amino acids, and acylcarnitine in dried blood spots. Clin Chem 2008; 54 (4): 657–664.

10. Dhillon KS, Bhandal AS, Aznar CP, et al. Improved tandem mass spectrometry (MS/MS) derivatized method for the detection of tyrosinemia type I, amino acids and acylcarnitine disorders using a single extraction process. Clin Chim Acta 2011; 412 (11–12): 873–879.

11. Lindblad B, Lindstedt S, Steen G. On the enzymatic defects in hereditary tyrosinemia. Proc Natl Acad Sci USA 1977; 74 (10): 4641–4645.

12. Vondráčková A, Tesařová M, Magner M, et al. Clinical, biochemical and molecular characteristics in 11 Czech children with tyrosinemia type I. Čas Lék čes 2010; 149 (9): 411–416.

13. Jakobs C, Dorland L, Wikkerink B, et al. Stable isotope dilution analysis of succinylacetone using electron capture negative ion mass fragmentography: an accurate approach to the pre- and neonatal diagnosis of hereditary tyrosinemia type I. Clin Chim Acta 1988; 17 (2–3): 1223–232.

14. Kvittingen EA, Holme E. Disorders of tyrosine metabolism. In: Fernandes JM, et al. Inborn Metabolic Diseases. 3rd ed. Heidelberg: Springer-Verlag, 2000: 186–194.

15. Chace DH, Lim T, Hansen CR, et al. Improved MS/MS analysis of succinylacetone extracted from dried blood spots when combined with amino acids and acylcarnitine butyl esters. Clin Chem Acta 2009; 407 (1–2): 6–9.

16. Laberge C, Grenier A, Valet JP, et al. Fumarylacetoacetase measurement as a mass-screening procedure for hereditary tyrosinemia type I. Am J Hum Genet 1990; 47 (2): 325–328.

17. Hasanoglu A, Ozalp I. Transient tyrosinemia of the newborn. Turk J Pediatr 1978; 20 (3–4): 85–90.

18. Manabe S, Sassa S, Kappas A. Hereditary tyrosinemia: formation of succinylacetone – amino acid adducts. J Exp Med 1985; 162 (3): 1060–1074.

19. Al-Dirbashi OY, Rashed MS, Ten Brink HJ, et al. Determination of succinylacetone in dried blood spots and liquid urine as a dansylhydrazone by liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 831 (1–2): 274–280.

20. Haagen AAM, Duran M. Absence of increased succinylacetone in the urine of a child with hereditary tyrosinemia type I. J Inherit Metab Dis 1987; 10 (Suppl 2): 323–325.

21. Rashed MS, Al-Ahaidib LY, Al-Dirbashi OY, et al. Tandem mass spectrometry assay of succinylacetone in urine for the diagnosis of hepatorenal tyrosinemia. Anal Biochem 2005; 339 (2): 310–317.

22. Chen H, Yu C. Urinary succinylacetone analysis by gas chromatography-mass spectrometry (GC-MS). In: Garg U. Clinical Applications of Mass Spectrometry in Biomolecular Analysis: Methods and Protocols. Heidelberg: Springer, 2016; 281–290.

23. Schulze A, Frommhold D, Hoffmann GF, et al. Spectrophotometric microassay for delta-aminolevulinate dehydratase in dried-blood spots as confirmation for hereditary tyrosinemia type I. Clin Chem 2001; 47 (8): 1424–1429.

24. Allard P, Grenier A, Korson MS, et al. Newborn screening for hepatorenal tyrosinemia by tandem mass spectrometry: analysis of succinylacetone extracted from dried blood spots. Clin Biochem 2004; 37 (11): 1010–1015.

25. Zytkovicz TH, Sahai I, Rush A, et al. Newborn screening for hepatorenal tyrosinemia-I by tandem mass spectrometry using pooled samples: a four-year summary by the New England newborn screening program. Clin Biochem 2013; 46 (7–8): 681–684.

26. Magera MJ, Gunawardena ND, Hahn SH, et al. Quantitative determination of succinylacetone in dried blood spots for newborn screening of tyrosinemia type I. Mol Genet Metab 2006; 88 (1): 16–21.

27. Laboratory Quality Improvement of Newborn Screening. http://www.clir-r4s.org/, Accessed July 7, 2014.

28. La Marca G, Malvagia S, Pasquini E, et al. The inclusion of succinylacetone as marker for tyrosinemia type I in expanded newborn screening programs. Rapid Commun Mass Spectrom 2008; 22 (6): 812–818.

29. Al-Dirbashi OY, Rashed MS, Jacob M, et al. Improved method to determine succinylacetone in dried blood spots for diagnosis of tyrosinemia type 1 using UPLC-MS/MS. Biomed Chrom 2008; 22 (11): 1181–1185.

30. Sander J, Janzen N, Peter M, et al. Newborn screening for hepatorenal tyrosinemia: tandem mass spectrometric quantification of succinylacetone. Clin Chem 2006; 52 (3): 482–487.

31. Lindstedt S, Holme E, Lock EA, et al. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 1992; 340 (8823): 813–817.

32. Lock EA, Ellis MK, Gaskin P, et al. From toxicological problem to therapeutic use: the discovery of the mode of action of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC), its toxicology and development as a drug. J Inherit Metab Dis 1998; 21 (5): 498–506.

33. Floriánková M, Bláhová Š, Pencová M, et al. Nutritional therapy in patients with inherited metabolic disorders. Čes-slov Pediat 2018; 73 (6): 395–407.

34. Larochelle J, Alvarez F, Bussieres JF, et al. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Quebec. Mol Genet Metab 2012; 107 (1–2): 49–54.

35. Sundberg J, Wibrand F, Lund AM, et al. Simultaneous quantification of succinylacetone and nitisinone for therapeutic drug monitoring in the treatment of Tyrosinemia type 1. J Chromatogr B Analyt Technol Biomed Life Sci 2018; 1072: 259–266.

36. Johnson DW, Gerace R, Ranieri E, et al. Analysis of succinylacetone, as a Girard T derivative, in urine and dried bloodspots by flow injection electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 2007; 21 (1): 59–63.